Fusion Antibodies (LSE:FAB) Capex-to-Operating-Income : 0.00 (As of Sep. 2023)

Fusion Antibodies Capex-to-Operating-Income Chart

Fusion Antibodies Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
Capex-to-Operating-Income		Get a 7-Day Free Trial				-	-	-	-	-

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Capex-to-Operating-Income	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Fusion Antibodies's Capex-to-Operating-Income

For the Biotechnology subindustry, Fusion Antibodies's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Capex-to-Operating-Income falls into.

Fusion Antibodies Capex-to-Operating-Income Calculation

Fusion Antibodies's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Fusion Antibodies's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies  (LSE:FAB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Fusion Antibodies Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description